Midadult women's attitudes about receiving the prophylactic human papillomavirus vaccine

Journal of Lower Genital Tract Disease

Volumn 11, Issue 3, 2007, Pages 166-172

  Ferris, Daron G ^a   Waller, Jennifer L ^a   Owen, Ashley ^a   Smith, Jozette ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b PAINE COLLEGE   (United States)

Author keywords

Acceptance; Attitudes; Human papillomavirus; Midadult women; Survey; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; ATTITUDE TO HEALTH; CANCER PREVENTION; FEAR; FEMALE; HEALTH EDUCATION; HUMAN; HUMAN RELATION; INFECTION RISK; QUESTIONNAIRE; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; VACCINATION;

ADULT; ATTITUDE TO HEALTH; FEMALE; HEALTH CARE SURVEYS; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT EDUCATION; RISK-TAKING; SAFE SEX; UTERINE CERVICAL NEOPLASMS;

EID: 34347353307     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1097/lgt.0b013e3180324114     Document Type: Article

References (18)

1. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A Controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
2. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
3. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27.
4. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. HPV Vaccine Study Group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006;367:1247-55.
5. Harper DM, Franco EL, Wheeler CM, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection of human papillomavirus type 16 and 18 in young women: a randomized controlled trial. Lancet 2004;364:1757-65.
6. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus 16 and 18: Follow-up from a randomized control trial. Lancet 2006;367:1247-55.
7. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
8. A human papillomavirus vaccine. Med Lett Drugs Ther 2006;48:65-6.
9. Davis K, Dickman ED, Ferris DG, Dias JK. Human papillomavirus vaccine acceptability among parents of 10 to 15 year old adolescents. J Lower Genital Tract Dis 2004;8:188-94.
10. Hoover DR, Carfioli B, Moench EA. Attitudes of adolescent/young adult women toward human papillomavirus vaccination and clinical trials. Health Care Women Int 2000;21:375-91.
11. Zimet GD, Mays RM, Winston Y, Kee R, Dickes J, Su L. Acceptability of human papillomavirus immunization. J Womens Health Gend Based Med 2000;9:47-50.
12. Kahn JA, Rosenthal SL, Hamann T, Bernstein DI. Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS 2003;14:300-6.
13. Boehner CW, Howe SR, Berstein DI, Rosenthal SL. Viral sexually transmitted disease vaccine acceptability among college students. Sex Transm Dis 2003;30:774-8.
14. Riche MF. America's diversity and growth: sign posts for the 21st century. Popul Bull 2000;55:1-43.
15. Blow AJ, Hartnett K. Infidelity in committed relationships II: a substantive review. J Marital Fam Ther 2005;31:217-33.
16. Liau A, Zimet GD, Fortenberry JD. Attitudes about human immunodeficiency virus immunization: the influence of health beliefs and vaccine characteristics. Sex Trasm Dis 1998;25:76-81.
17. Olshen E, Woods ER, Austin SB, Luskin M, Bauchner H. Parental acceptance of the human papillomavirus vaccine. J Adolesc Health 2005;37:248-51.
18. Lazcano-Ponce E, Rivera L, Arillo-Santillan E, Salmeron J, Hernandez-Avila M, Munoz N. Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico. Arch Med Res 2001;32:243-7.